During the academic studies Giulia became fascinated by the field of hematopoiesis and in particular by the complex regulation of hematopoietic stem cells (HSC) in healthy and malignant conditions.
As a M.Sc. student she joined in 2013 L. Naldini’s Laboratory (SR-TIGET, Milan), which has a world leading expertise in advanced manipulation of HSC for therapeutic purposes. Her Ph.D. studies focused on the development of novel targeted gene editing approaches to safely engineer human HSC and the establishment of in vivo preclinical models to determine the conditions for safe and effective HSC gene editing. After obtaining the Ph.D. in 2017, she investigated the cellular responses to the DNA break induced by engineered nucleases in HSC by single cell transcriptomic approaches.
In June 2018 she moved to Dr. David Scadden’s Laboratory in Massachusetts General Hospital (Boston) as a Postdoctoral fellow. The project she is undertaking now, which is supported by American-Italian Cancer Foundation (AICF), is aimed to investigate the cell-specific HSC determinants involved in cancer progression in individuals with clonal hematopoiesis, with the final goal to elucidate risk factors for malignant transformation.